Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Quest Diagnostics

Share:
Related DGX
Earnings Scheduled For January 26, 2017
Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector
Veracyte: An Ideal Medium-Term Runner With Long-Term Upside (Seeking Alpha)

In a report published Monday, Jefferies & Company reiterated its Hold rating on Quest Diagnostics (NYSE: DGX), but lowered its price target from $63.00 to $59.00.

Jefferies noted, “We continue to have a neutral view on DGX given our belief that ongoing weakness in lab volumes will persist and keep the stock rangebound near-term. While we are optimistic that mgmt's efforts to restructure operations and rationalize expenses will achieve their targets, we recognize that this process, which could be the key catalyst for the stock, will take time to complete.”

Quest Diagnostics closed on Friday at $57.94.

Latest Ratings for DGX

DateFirmActionFromTo
Jan 2017Deutsche BankInitiates Coverage OnBuy
Jan 2017Deutsche BankInitiates Coverage OnBuy
Jan 2017MizuhoUpgradesNeutralBuy

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (DGX)

View Comments and Join the Discussion!